Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund
Appointment of Dr. William Jeffrey to the Board and Bonnie Tomei as CFO
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/
Image by Shabbir Bashar
“What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant power savings. The completion of this round will further our development and help us bring our product to customers to enable not just the savings, but large cluster connectivity,” said Vaysh Kewada, Co-founder and CEO of Salience Labs. “We are also excited to be working closely with our strategic investors who are industry leaders to advance our go-to market schedule.”
“Silicon photonics is a promising technology to deliver significant advancements in energy-efficient performance for AI data centers,” said Anand Kamannavar, Vice President and Global Head of Applied Ventures. “Salience's optical switch solution has the potential to enable a new generation of interconnect network architectures for faster and more efficient AI systems.”
“Salience Labs has done a tremendous job in developing a portfolio of innovative silicon photonics products that addresses critical needs in data center and AI infrastructure market,” said Dr. Jalal Bagherli, investor of Salience Labs and former CEO of Dialog Semiconductor that was acquired by Renesas. “Their customer focused approach in addition to the technology that are based on over a decade of research makes Salience Labs a clear leader to win in this enormous market.”
“Salience Lab’s optical switches will enable unprecedented bandwidth and scalability for the next generation of AI and high-performance data centers. By leveraging light, they will unlock the full capability of modern servers while decreasing power consumption and cost. ICM HPQC is excited to work with Vaysh and the Salience team as lead of the Series A raise,” said Dr. William Jeffrey, Chairman of the technical advisory committee on the ICM HPQC Fund and newly appointed Board Member of Salience Labs.
Appointment of Dr. William Jeffrey as new Board Member
In conjunction with the closing of the Series A financing, Salience Labs is appointing Dr. Jeffrey to the Board of Directors, where he joins Jack Edmondson, Chief Investment Officer of Oxford Sciences Enterprises, and Daniel Armbrust, co-founder of Silicon Catalyst, CEO of the SEMATECH semiconductor consortium and appointee to the Industrial Advisory Committee, which advises the Department of Commerce on the R&D strategy for the CHIPS Act.
Dr. Jeffrey is an astronomer with a career spanning the Executive Office of the President of the United States, to leading HRL (known for its groundbreaking innovations such as the invention of the laser, integrated circuits and liquid crystal displays), to being the Director of the National Institute of Standards and Technology, an institution boasting three Nobel prize laureates and ties to a dozen more, and he served as the CEO of SRI International. Dr. Jeffrey earned a Bachelor of Science in physics from the Massachusetts Institute of Technology and a Ph.D. in astronomy from Harvard University.
Appointment of Bonnie Tomei as Chief Financial Officer
Salience Labs is also announcing its appointment of Bonnie Tomei, a certified public accountant and an industry veteran located in Silicon Valley, California, as Chief Financial Officer.
“With over 20 years of experience including initial public offerings, de-SPAC and a strong business operations background, Ms. Tomei will be a key member of the executive team to realize our strategic and operational objectives, including expanding to the U.S. to serve our key customers,” said Ms. Kewada.
About Salience Labs
Salience Labs Limited is a leader in photonic solutions targeting connectivity for AI datacenter infrastructure. Founded in 2021 and backed by over a decade of research from the University of Oxford in the UK and University of Münster in Germany, Salience’s innovative developments in photonic switching technology enable high-speed, ultra-low latency networking fabrics that remove infrastructure bottlenecks for AI workloads. Learn more at http://www.saliencelabs.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207290130/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom